| dc.contributor.advisor | Poetri, Okti Nadia | |
| dc.contributor.advisor | Nugroho, Christian Marco Hadi | |
| dc.contributor.author | Hikmah, Nur | |
| dc.date.accessioned | 2023-07-10T13:42:49Z | |
| dc.date.available | 2023-07-10T13:42:49Z | |
| dc.date.issued | 2023-07-10 | |
| dc.identifier.uri | http://repository.ipb.ac.id/handle/123456789/121295 | |
| dc.description.abstract | Virus avian influenza (VAI) subtipe H9N2 mengancam industri unggas dan kesehatan masyarakat karena berpotensi zoonotik. Antiviral berbasis sialidase dikembangkan sebagai upaya pencegahan dan pengobatan infeksi virus seperti VAI yang memerlukan sialic acid pada point of entry ke dalam sel. Penelitian ini bertujuan menganalisis potensi NanB sialidase asal Pasteurella multocida dalam menghambat infeksi virus avian influenza subtype H9N2 (VAI-H9N2) secara in ovo. Strain A/Layer/Indonesia/WestJava-04/17 dan NanB sialidase yang digunakan dalam penelitian ini berasal dari PT. Medika Satwa Laboratoris. Virus diidentifikasi ulang dengan quantitative real-time polymerase chain reaction (qRT-PCR) dan ditentukan titer virusnya embryo infectious dose (EID)50. Toksisitas NanB sialidase diuji terhadap beberapa dosis secara in ovo. Uji tantang virus dilakukan untuk menentukan aktivitas antiviral NanB Sialidase, menggunakan telur ayam berembrio (TAB) dengan tiga perlakuan yaitu: pemberian sebelum, saat, dan setelah ditantang. Hasil penelitian menunjukkan bahwa titer virus adalah 108,83 EID50/ml. Dosis efektif dan tidak toksis NanB sialidase dalam menghambat infeksi virus pada TAB yaitu dosis 0,129 U/ml. Kelompok pemberian sialidase setelah tantang menunjukkan aktivitas antiviral NanB sialidase yang paling efektif. Studi ini menunjukkan potensi NanB sialidase asal Pasteurella multocida sebagai antiviral VAI dengan pendekatan terapeutik. | id |
| dc.description.abstract | Avian influenza virus (AIV) subtype H9N2 threatens the poultry industry and public health due to its zoonotic potential. Antivirals based on sialidase have been developed as a prevention and treatment measure for viral infections such as AIV, which require sialic acid at the point of entry into cells. This study aims to analyze NanB sialidase of Pasteurella multocida ability to inhibit avian influenza virus subtype H9N2 (AIV-H9N2) infection in ovo. The strain A/Layer/Indonesia/WestJava-04/17 and NanB sialidase used in this study were belong to PT. Medika Satwa Laboratoris. The virus was re-identified using quantitative real-time polymerase chain reaction (qRT-PCR) and embryo infectious dose (EID)50 was determined. NanB sialidase toxicity was tested at several doses in ovo. Virus challenge test was conducted to determine antiviral activity of NanB sialidase, using embryonated chicken eggs (ECE), with three treatments: before, during, and after challenge. The results showed that the virus titer is 108,83 EID50/ml. Effective and non-toxic dose of NanB sialidase to virus infection in ECE was 0,129 U/ml. The group given sialidase after challenge showed the most effective antiviral activity of NanB sialidase. This study demonstrates potential of NanB sialidase from Pasteurella multocida as an antiviral for AIV with a therapeutic approach. | id |
| dc.description.sponsorship | PT. Medika Satwa Laboratoris, Bogor | id |
| dc.language.iso | id | id |
| dc.publisher | IPB University | id |
| dc.title | Potensi NanB Sialidase Asal Bakteri Pasteurella multocida dalam Menghambat Replikasi Virus Avian Influenza H9N2 secara In Ovo | id |
| dc.title.alternative | The Potential of NanB Sialidase from Pasteurella multocida Bacteria in Inhibiting Replication of Avian Influenza Virus H9N2 In Ovo | id |
| dc.type | Undergraduate Thesis | id |
| dc.subject.keyword | Antiviral | id |
| dc.subject.keyword | In ovo | id |
| dc.subject.keyword | NanB sialidase | id |
| dc.subject.keyword | Pasteurella multocida | id |
| dc.subject.keyword | VAI-H9N2 | id |
